- Home
- LX vs SNDX Comparison
LX vs SNDX Comparison
Compare LX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- SNDX
- Stock Information
- Founded
- LX 2013
- SNDX 2005
- Country
- LX China
- SNDX United States
- Employees
- LX N/A
- SNDX N/A
- Industry
- LX Finance: Consumer Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- LX Finance
- SNDX Health Care
- Exchange
- LX Nasdaq
- SNDX Nasdaq
- Market Cap
- LX 1.3B
- SNDX 1.1B
- IPO Year
- LX 2017
- SNDX 2016
- Fundamental
- Price
- LX $6.14
- SNDX $9.99
- Analyst Decision
- LX
- SNDX Strong Buy
- Analyst Count
- LX 0
- SNDX 11
- Target Price
- LX N/A
- SNDX $34.00
- AVG Volume (30 Days)
- LX 4.5M
- SNDX 1.7M
- Earning Date
- LX 08-26-2025
- SNDX 08-04-2025
- Dividend Yield
- LX 2.94%
- SNDX N/A
- EPS Growth
- LX 35.86
- SNDX N/A
- EPS
- LX 1.07
- SNDX N/A
- Revenue
- LX $1,938,367,396.00
- SNDX $43,722,000.00
- Revenue This Year
- LX $2.38
- SNDX $431.08
- Revenue Next Year
- LX $8.71
- SNDX $105.38
- P/E Ratio
- LX $6.00
- SNDX N/A
- Revenue Growth
- LX 5.63
- SNDX N/A
- 52 Week Low
- LX $1.57
- SNDX $8.58
- 52 Week High
- LX $11.64
- SNDX $23.37
- Technical
- Relative Strength Index (RSI)
- LX 36.62
- SNDX 52.52
- Support Level
- LX $6.88
- SNDX $9.42
- Resistance Level
- LX $7.99
- SNDX $10.54
- Average True Range (ATR)
- LX 0.39
- SNDX 0.57
- MACD
- LX -0.05
- SNDX 0.10
- Stochastic Oscillator
- LX 0.00
- SNDX 56.80
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.